UY34603A - Anticuerpos anti-asic-1 y usos de los mismos - Google Patents

Anticuerpos anti-asic-1 y usos de los mismos

Info

Publication number
UY34603A
UY34603A UY34603A UY34603A UY34603A UY 34603 A UY34603 A UY 34603A UY 34603 A UY34603 A UY 34603A UY 34603 A UY34603 A UY 34603A UY 34603 A UY34603 A UY 34603A
Authority
UY
Uruguay
Prior art keywords
asic
antibodies
same
figura
hay
Prior art date
Application number
UY34603A
Other languages
English (en)
Inventor
Mcdonald Lynn
Gao Min
Marc R Morra
Nicole M Alessandri Haber
Michael L Lacroix-Fralish
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47666522&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY34603(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of UY34603A publication Critical patent/UY34603A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención proporciona anticuerpos y fragmentos de unión a antígeno de los mismos que se unen específicamente a células que expresan el canal iónico sensible al ácido de tipo 1 (ASIC1). De acuerdo con ciertas realizaciones de la invención, los anticuerpos inhiben las corrientes iónicas mediadas por ASIC1, inducidas por ácido en células que expresan ASIC1 humana. Los anticuerpos de la invención son útiles para el tratamiento del dolor, incluyendo el dolor asociado con intervenciones q uirúrgicas y diversas enfermedades y trastornos.
UY34603A 2012-01-31 2013-01-31 Anticuerpos anti-asic-1 y usos de los mismos UY34603A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261592837P 2012-01-31 2012-01-31
US201261644038P 2012-05-08 2012-05-08
US201261692925P 2012-08-24 2012-08-24

Publications (1)

Publication Number Publication Date
UY34603A true UY34603A (es) 2013-07-31

Family

ID=47666522

Family Applications (1)

Application Number Title Priority Date Filing Date
UY34603A UY34603A (es) 2012-01-31 2013-01-31 Anticuerpos anti-asic-1 y usos de los mismos

Country Status (33)

Country Link
US (3) US9150648B2 (es)
EP (2) EP3453723B1 (es)
JP (1) JP6302844B2 (es)
KR (1) KR102111941B1 (es)
CN (1) CN104093738B (es)
AR (1) AR089852A1 (es)
AU (1) AU2013215254B2 (es)
CA (1) CA2862332C (es)
CL (1) CL2014002019A1 (es)
CO (1) CO7020877A2 (es)
CY (2) CY1121368T1 (es)
DK (2) DK3453723T3 (es)
EA (1) EA028647B1 (es)
ES (2) ES2886123T3 (es)
HR (2) HRP20190358T1 (es)
HU (2) HUE056335T2 (es)
IL (2) IL233410A0 (es)
IN (1) IN2014CN04645A (es)
JO (1) JO3547B1 (es)
LT (2) LT3453723T (es)
MX (1) MX358518B (es)
MY (1) MY168748A (es)
NZ (1) NZ626242A (es)
PH (1) PH12014501613A1 (es)
PL (2) PL2809681T3 (es)
PT (2) PT2809681T (es)
RS (2) RS62454B1 (es)
SG (1) SG11201403222UA (es)
SI (2) SI3453723T1 (es)
SM (1) SMT202100628T1 (es)
TW (1) TWI591073B (es)
UY (1) UY34603A (es)
WO (1) WO2013116296A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013215254B2 (en) 2012-01-31 2017-08-31 Regeneron Pharmaceuticals, Inc. Anti-ASIC1 antibodies and uses thereof
AU2015247742A1 (en) 2014-04-15 2016-11-24 Sorrento Therapeutics, Inc. Antigen binding proteins that bind WISP1
IL318433A (en) 2014-05-16 2025-03-01 Ablynx Nv Improved immunoglobulin variable complexes
SG11201609162SA (en) 2014-05-16 2016-12-29 Ablynx Nv Improved immunoglobulin variable domains
CN105233286B (zh) * 2015-09-10 2018-10-30 上海交通大学医学院 含酸敏感离子通道调控剂的制剂及其在治疗瘙痒中的用途
CN105713089B (zh) * 2016-02-26 2019-08-06 上海科技大学 一种特异性抑制酸敏感离子通道i型的全人抗体
WO2018085441A1 (en) * 2016-11-01 2018-05-11 Berg Llc Filamin b binding proteins and uses thereof
BR112020015112A2 (pt) * 2018-01-26 2021-04-06 Regeneron Pharmaceuticals, Inc. Anticorpos anti-tmprss2 e fragmentos que ligam antígenos
CN114729034B (zh) * 2019-06-04 2024-01-12 上海科技大学 亲和力成熟的抗ASIC1a抗体
BR112022000216A2 (pt) * 2019-07-11 2022-05-17 Memorial Sloan Kettering Cancer Center Anticorpos direcionados a dll3 e usos dos mesmos
WO2021012176A1 (en) * 2019-07-23 2021-01-28 Shanghaitech University Asic1 channel antagonist antibody
JP7796008B2 (ja) * 2019-09-13 2026-01-08 メモリアル スローン ケタリング キャンサー センター 抗ｃｄ３７１抗体およびその使用
WO2023019121A2 (en) * 2021-08-09 2023-02-16 Merck Patent Gmbh Proteins that decouple t cell-mediated tumor cytotoxicity from release of pro-inflammatory cytokines
EP4396224A4 (en) * 2021-09-02 2025-11-12 Memorial Sloan Kettering Cancer Center Anti-DLL3 Antibodies and Their Uses
JP2024083709A (ja) * 2022-12-12 2024-06-24 ａｒｔｉｅｎｃｅ株式会社 コート剤、シートおよび成形体
CN119331085B (zh) * 2024-10-16 2025-03-14 中国科学院合肥物质科学研究院 沙贝冠状病毒广谱中和抗体及其应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2759373B1 (fr) 1997-02-11 2001-05-04 Centre Nat Rech Scient Nouveau canal cationique neuronal de mammifere sensible a l'acidite, son clonage et ses applications
ES2279583T3 (es) 1997-10-29 2007-08-16 Mcgill University Adn que codifica para un canal ionico regulado por protones humano y usos del mismo.
US6287859B1 (en) 1998-08-05 2001-09-11 Centre National De La Recherche Identification, functional expression and chromosal localization of a sustained human proton-gated cation channel
CA2304494A1 (en) 2000-04-20 2001-10-20 Philippe Seguela A novel heteromultimeric ion channel receptor and uses thereof
US6635432B1 (en) 2000-04-25 2003-10-21 University Of Iowa Research Foundation Peptide potentiation of acid-sensory ion channel in pain
US7132505B1 (en) 2001-05-10 2006-11-07 Centre National De La Recherche Scientifique - Cnrs Polypeptide inhibiting a proton-gated Na+ channel, a nucleic acid coding for such polypeptide and a method of manufacturing an ASIC1a channel blocker
CA2352702A1 (en) * 2001-07-18 2003-01-18 Philippe Seguela Novel human proton gated ion channel
AR039067A1 (es) * 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
ATE435239T1 (de) * 2002-03-29 2009-07-15 Schering Corp Menschliche monoklonale antikörper gegen interleukin-5 sowie diese umfassende verfahren und zusammensetzungen
US20030186860A1 (en) 2002-03-29 2003-10-02 Welsh Michael J. Novel compositions and methods for modulating the acid-sensing ion channel (ASIC)
US20070197583A1 (en) 2002-03-29 2007-08-23 Welsh Michael J Novel compositions and methods for modulation of the acid-sensing ion channel (ASIC) for the treatment of anxiety and drug addiction
WO2005025518A2 (en) * 2003-09-11 2005-03-24 The Uab Research Foundation Inhibition of inward sodium currents in cancer
WO2005074923A1 (en) 2004-02-03 2005-08-18 Agt Biosciences Limited Methods and compositions
EP1734962A4 (en) 2004-03-30 2010-07-14 Painceptor Pharma Corp COMPOSITIONS AND METHOD FOR MODULATING CONTROLLED ION CHANNELS
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
US7192500B2 (en) 2004-04-30 2007-03-20 Kimberly-Clark Worldwide, Inc. Process for making a garment including an absorbent assembly
US8030442B2 (en) 2004-09-16 2011-10-04 Morehouse School Of Medicine Treatment of injury to the brain by inhibition of acid sensing ion channels
ES2371083T3 (es) * 2004-12-21 2011-12-27 Medimmune Limited Anticuerpos dirigidos contra la angiopoyetina-2 y usos de los mismos.
NZ562234A (en) * 2005-04-26 2009-09-25 Pfizer P-cadherin antibodies
NZ587107A (en) 2006-06-02 2012-05-25 Regeneron Pharma High affinity antibodies to human il-6 receptor
WO2008007648A1 (fr) * 2006-07-10 2008-01-17 Institute For Antibodies Co., Ltd. Procédé de classification d'antigène, procédé d'identification d'antigène, procédé d'obtention d' un ensemble d'antigènes ou d'anticorps, procédés de construction d'un panel d'anticorps, anticorps et ens
WO2008007131A2 (en) * 2006-07-14 2008-01-17 Medical Research Council Treatment for demyelinating disease
RU2448979C2 (ru) * 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
US7598039B2 (en) 2007-01-30 2009-10-06 Academia Sinica Treatment of insulin resistance
DE602008002913D1 (de) 2007-04-03 2010-11-18 Ilegusavnid Genetics Resource Mit panikstörungen assoziierte amilorid-sensitive natriumkanäle
ES2465223T3 (es) * 2007-04-27 2014-06-05 Zymogenetics, Inc. Antagonistas de IL-17A, IL-17F e IL-23P19 y procedimientos de uso
WO2009137686A1 (en) * 2008-05-08 2009-11-12 University Of Utah Research Foundation Sensory receptors for chronic fatigue and pain and uses thereof
US20090291150A1 (en) 2008-05-21 2009-11-26 University Of Iowa Research Foundation Method and compositions for treating and preventing seizures by modulating acid-sensing ion channel activity
FR2932091B1 (fr) 2008-06-06 2012-12-28 Centre Nat Rech Scient Effets analgesiques de la toxine peptidique apetx2
WO2010054007A1 (en) * 2008-11-07 2010-05-14 Fabrus Llc Combinatorial antibody libraries and uses thereof
JO3672B1 (ar) * 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US8926976B2 (en) * 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
GB0922434D0 (en) 2009-12-22 2010-02-03 Ucb Pharma Sa antibodies and fragments thereof
CN102234316B (zh) * 2010-05-07 2014-01-29 中国人民解放军军事医学科学院毒物药物研究所 具有增强酸感受离子通道1a电流作用的多肽及其用途
AU2013215254B2 (en) 2012-01-31 2017-08-31 Regeneron Pharmaceuticals, Inc. Anti-ASIC1 antibodies and uses thereof
US9371383B2 (en) 2012-01-31 2016-06-21 Regeneron Pharmaceuticals, Inc. Anti-ASIC1 antibodies and uses thereof

Also Published As

Publication number Publication date
CA2862332A1 (en) 2013-08-08
CN104093738B (zh) 2018-05-18
RS62454B1 (sr) 2021-11-30
HUE042531T2 (hu) 2019-07-29
EP3453723B1 (en) 2021-08-11
EA201491452A1 (ru) 2014-11-28
PH12014501613B1 (en) 2014-10-13
SMT202100628T1 (it) 2022-01-10
NZ626242A (en) 2017-02-24
EP3453723A2 (en) 2019-03-13
MY168748A (en) 2018-11-30
KR20140125363A (ko) 2014-10-28
JO3547B1 (ar) 2020-07-05
AR089852A1 (es) 2014-09-24
MX2014008541A (es) 2014-10-24
TW201335182A (zh) 2013-09-01
TWI591073B (zh) 2017-07-11
PL2809681T3 (pl) 2019-05-31
HUE056335T2 (hu) 2022-02-28
DK2809681T3 (en) 2019-03-11
RS58439B1 (sr) 2019-04-30
PT3453723T (pt) 2021-09-07
IN2014CN04645A (es) 2015-09-18
ES2707599T3 (es) 2019-04-04
IL233410A0 (en) 2014-08-31
AU2013215254B2 (en) 2017-08-31
HRP20211541T1 (hr) 2021-12-24
PT2809681T (pt) 2019-02-18
PH12014501613A1 (en) 2014-10-13
SI2809681T1 (sl) 2019-04-30
JP6302844B2 (ja) 2018-03-28
CY1121368T1 (el) 2020-05-29
KR102111941B1 (ko) 2020-05-18
LT3453723T (lt) 2021-09-10
CO7020877A2 (es) 2014-08-11
EA028647B1 (ru) 2017-12-29
IL254416A0 (en) 2017-11-30
PL3453723T3 (pl) 2022-01-03
US10513557B2 (en) 2019-12-24
US20180222976A1 (en) 2018-08-09
CL2014002019A1 (es) 2015-01-16
WO2013116296A1 (en) 2013-08-08
AU2013215254A1 (en) 2014-07-03
EP2809681B1 (en) 2018-12-05
IL254416B (en) 2018-03-29
JP2015508063A (ja) 2015-03-16
SI3453723T1 (sl) 2021-11-30
CY1124778T1 (el) 2022-11-25
HRP20190358T1 (hr) 2019-04-05
CN104093738A (zh) 2014-10-08
DK3453723T3 (da) 2021-09-13
EP3453723A3 (en) 2019-04-10
MX358518B (es) 2018-08-24
US20160002332A1 (en) 2016-01-07
CA2862332C (en) 2021-05-18
LT2809681T (lt) 2019-02-11
EP2809681A1 (en) 2014-12-10
US9150648B2 (en) 2015-10-06
SG11201403222UA (en) 2014-07-30
HK1199269A1 (en) 2015-06-26
ES2886123T3 (es) 2021-12-16
US20130195878A1 (en) 2013-08-01
BR112014018651A2 (pt) 2017-07-04

Similar Documents

Publication Publication Date Title
FR22C1048I2 (fr) Anticorps anti-cd3 et méthodes d'utilisation
UY34876A (es) Anticuerpos anti-egfr y usos de los mismos
UY34721A (es) Anticuerpos anti-hla-b*27 y usos de éstos.
UY34271A (es) Anticuerpos anti-tie2 y usos de los mismos
CL2016000251A1 (es) Anticuerpos anti-activina y usos de los mismos
UY34680A (es) Anticuerpos humanos anti-cd27, métodos, y usos
UY34782A (es) Anticuerpos humanos para fel d1 y métodos para usarlos.
CO7020877A2 (es) Anticuerpos anti-asic1 y usos de los mismos
CL2015001321A1 (es) Anticuerpos anti-ceacam5 y usos de éstos
EA201590993A1 (ru) Гетеродимерные иммуноглобулины
MX385585B (es) Anticuerpos anti-c10orf54 y usos de los mismos.
UY34538A (es) Heteroarilos y usos de los mismos
SMT201700003B (it) Didropiridoni come inibitori del fattore xia
CO6821892A2 (es) Anticuerpos anti-angptl3 y usos de los mismos
CO6940383A2 (es) Anticuerpos anti-erbb3 y usos de los mismos
DK2806892T3 (da) Kombineret terapeutisk anvendelse af antistoffer og endoglycosidaser
MX364714B (es) Animales no humanos geneticamente modificados y metodos de uso de los mismos.
EA201491357A1 (ru) Анти-lrp5 антитела и способы их применения
JOP20140114B1 (ar) مركبات حلقية غير متجانسة واستخداماتها
EA201491947A1 (ru) Антитела и иммуноконъюгаты к ly6e и способы применения
PL3067358T3 (pl) Policykliczne związki karbamoilopirydonu i ich zastosowanie farmaceutyczne
PL2922850T3 (pl) Związki i sposoby ich stosowania
CO6940376A2 (es) Anticuerpos anti-psgl-1 y usos de los mismos
HRP20170840T1 (hr) Supstituirani ksantini i metode njihove uporabe
BR112014026926A2 (pt) uso terapêutico de produtos de semente de chardonnay

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20220104